Evidence map›Paper›PMID 29405520›Full record

ArticleAddiction (Abingdon, England)2018

Do predictors of smoking relapse change as a function of duration of abstinence? Findings from the United States, Canada, United Kingdom and Australia.

Hua-Hie Yong, Ron Borland, K Michael Cummings, Timea Partos

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Comparison of smoking prevalence in Canada before and after nicotine vaping product access using the SimSmoke model.Canadian journal of public health = Revue canadienne de sante publique · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hua-Hie YongNigel Gray Fellowship Group, Cancer Council Victoria, Melbourne, Australia.ORCID 0000-0001-8167-6173
Ron BorlandNigel Gray Fellowship Group, Cancer Council Victoria, Melbourne, Australia.
K Michael CummingsDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.
Timea PartosDepartment of Addictions, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.

Funding

Vaporized Nicotine Product Initiation Among Youth in the US, Canada, and England: Methods to Predict Uptake and Policy EfficacyP01CA200512 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HAMMOND, DAVID · 2016 to 2025
$25.3M
Variation in Cigarettes, Tobacco use Behaviors and Exposures in ITC CountriesP01CA138389 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CUMMINGS, KENNETH MICHAEL · 2009 to 2013
$13.4M
Project 3: Policy Effects on Cigarette Design, Emissions &BehaviorP50CA111236 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CUMMINGS, KENNETH MICHAEL · 2004 to 2009
$8.2M
International Tobacco Policy SurveyR01CA100362 · NCI · UNIVERSITY OF WATERLOO · PI FONG, GEOFFREY T · 2005 to 2013
$4.7M
CIHR 115016CIHR 79551NCI NIH HHS P01 CA138389NCI NIH HHS P01 CA200512NCI NIH HHS P50 CA111236NCI NIH HHS R01 CA100362
6 · The paper itself

Abstract

aimsTo estimate predictors of time to smoking relapse and test if prediction varied by quit duration.

designLongitudinal cohort data from the International Tobacco Control Four-Country survey with annual follow up collected between 2002 and 2015.

settingCanada, United States, United Kingdom and Australia.

participantsA total of 9171 eligible adult smokers who had made at least one quit attempt during the study period. MEASUREMENTS: Time to relapse was the main outcome. Predictor variables included pre-quit baseline measures of nicotine dependence, smoking and quitting-related motivations, quitting capacity and social influence, and also two post-quit measures, use of stop-smoking medications and quit duration (1-7 days, 8-14 days, 15-31 days, 1-3 months, 3-6 months, 6-12 months, 1-2 years and 2+ years), along with socio-demographics.

findingsAll factors were predictive of relapse within the first 6 months of quitting but only wanting to quit, quit intentions and number of friends who smoke were still predictive of relapse in the 6-12-month period of quitting [hazard ratios (HR) = 1.20, P < 0.05; 1.13, P < 0.05; and 1.21, P < 0.001, respectively]. Number of friends smoking was the only remaining predictor of relapse in the 1-2 years quit period (HR = 1.19, P = 0.001) with none predictive beyond the 2-year quit period. Use of stop-smoking medications during quit attempts was related negatively to relapse during the first 2 weeks of quitting (HR = 0.71-0.84), but related positively to relapse in the 1-6-month quit period (HR = 1.29-1.54). Predictive effects of all factors showed significant interaction with quit duration except for perceiving smoking as an important part of life, prematurely stubbing out a cigarette and wanting to quit.

conclusionsAmong adult smokers in the United States, Canada, United Kingdom and Australia, factors associated with smoking relapse differ between the early and later stages of a quit attempt, suggesting that the determinants of relapse change as a function of abstinence duration.

Indexed as

MotivationSmoking CessationSocial EnvironmentAdolescentAdultAustraliaCanadaCohort StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedRecurrenceRisk FactorsSmokingSmoking Cessation AgentsAdult smokersduration of abstinencepredictorssmoking relapsesurvival analysistime-varying effects

Identifiers

PMID29405520
PMCPMC5993599

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.